Alzheimer’s Anti-Amyloid Drugs in 2026: Who Qualifies, What Are the Risks, and What Medicare Covers

Why anti-amyloid drugs are still making headlines in 2026

Anti-amyloid monoclonal antibodies are now part of real-world Alzheimer’s care in the United States. For families facing early memory loss, they represent a new option—but not a cure.

These drugs, including lecanemab (brand name Leqembi), are designed to remove amyloid plaques from the brain. Amyloid is one of the abnormal proteins that builds up in Alzheimer’s disease. Clearing amyloid may slow disease progression, especially in the earliest symptomatic stages.

The key point: these medications may modestly slow cognitive decline in certain patients. They do not reverse memory loss, and they are not appropriate for moderate or advanced Alzheimer’s disease.

Understanding who qualifies, what the evidence shows, and what Medicare actually covers can help families make informed decisions.

What are anti-amyloid monoclonal antibodies?

Monoclonal antibodies are laboratory-made immune proteins. In Alzheimer’s disease, anti-amyloid antibodies are designed to attach to amyloid-beta plaques in the brain and help the body clear them.

According to the U.S. Food and Drug Administration (FDA), lecanemab received traditional approval for patients with early Alzheimer’s disease—specifically those with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s, and confirmed amyloid pathology.

These drugs target one part of the disease process. They do not repair neurons that have already been damaged, and they do not restore lost cognitive function.

Who qualifies under FDA labeling?

Under FDA approval, lecanemab is indicated for:

People with mild cognitive impairment due to Alzheimer’s disease, or
People with mild Alzheimer’s dementia,
With confirmed evidence of amyloid in the brain.

Confirmation of amyloid typically requires a PET scan or cerebrospinal fluid (CSF) testing. Blood tests for amyloid-related markers are emerging and increasingly used for screening, but PET or CSF confirmation remains the standard pathway for treatment eligibility.

These medications are not approved for moderate or severe Alzheimer’s disease.

What the main clinical trial showed—and what it did not

The pivotal evidence for lecanemab comes from the CLARITY-AD trial, a large randomized, placebo-controlled study published in the New England Journal of Medicine.

The trial enrolled about 1,800 participants with early symptomatic Alzheimer’s disease and followed them for 18 months. Participants were randomly assigned to receive either lecanemab or placebo.

The main outcome measure was the Clinical Dementia Rating–Sum of Boxes (CDR-SB), a scale that measures memory, thinking, and daily function.

After 18 months, the lecanemab group showed a 27% relative slowing of decline compared with placebo. In practical terms, this translated to a difference of 0.45 points on the CDR-SB scale.

For families, this means the drug slowed progression by several months on average during the study period. It did not stop the disease or improve cognition back to baseline.

Important limitations:

The study followed patients for 18 months; long-term durability of benefit is still being studied.
Participants were carefully selected and monitored; real-world patients may have more complex medical conditions.
The benefit is statistically significant but modest in magnitude.

Understanding ARIA and other risks

The most important safety issue with anti-amyloid drugs is ARIA, short for amyloid-related imaging abnormalities.

ARIA can involve:

ARIA-E: brain swelling (edema)
ARIA-H: small areas of bleeding (microhemorrhages)

In the CLARITY-AD trial, ARIA occurred in a significant minority of treated patients. Many cases were asymptomatic and found only on MRI. However, some patients experienced symptoms such as headache, confusion, dizziness, nausea, or visual changes.

Serious complications were uncommon but did occur.

Risk is higher in people who carry the APOE ε4 gene variant, especially those with two copies. APOE testing is not mandatory everywhere, but many specialists recommend discussing genetic testing to better understand ARIA risk before starting treatment.

Because of ARIA risk, the FDA requires MRI monitoring before and during treatment.

What testing and monitoring are required?

Starting an anti-amyloid medication is not as simple as writing a prescription. It typically involves:

Comprehensive cognitive evaluation by a neurologist or dementia specialist.
Confirmation of amyloid pathology with PET imaging or CSF testing.
Baseline MRI to check for preexisting microbleeds or other abnormalities.
Ongoing MRI scans during the first months of treatment to monitor for ARIA.
Regular follow-up visits to assess symptoms and side effects.

Lecanemab is given as an intravenous (IV) infusion every two weeks. This requires access to an infusion center and often caregiver support for transportation and monitoring.

How Medicare coverage works in practice

Medicare coverage for anti-amyloid monoclonal antibodies has evolved. According to the Centers for Medicare & Medicaid Services (CMS), Medicare covers FDA-approved anti-amyloid drugs under specific conditions.

Key elements include:

The drug must have traditional FDA approval.
The patient must be enrolled in a registry that collects real-world data.
The treating clinician must document appropriate use consistent with FDA labeling.

This registry requirement allows Medicare to track safety and effectiveness outside of clinical trials.

Patients are still responsible for standard Part B cost-sharing (such as coinsurance), unless they have supplemental coverage. Out-of-pocket costs can vary depending on secondary insurance, infusion facility charges, and imaging expenses.

Families should ask their care team and insurance provider for a clear explanation of expected costs before starting therapy.

Practical realities: infusions, caregiving, and access

Beyond clinical eligibility, practical considerations matter.

Infusion schedule: Every two weeks means frequent visits.
MRI monitoring: Multiple scans in the first year.
Caregiver involvement: Someone often needs to accompany the patient.
Geographic access: Rural patients may face longer travel times to infusion centers or PET imaging facilities.

For some families, the logistics and time commitment are manageable. For others, they may be a major barrier.

What remains uncertain

Several important questions remain:

How durable is the benefit beyond 18 months?
Will real-world outcomes match clinical trial results?
What are the long-term safety risks with extended treatment?
How will emerging blood-based biomarker tests change eligibility and monitoring?

Researchers continue to study these issues, and registry data collected under Medicare coverage may provide additional answers in the coming years.

Questions to ask your doctor

Am I in the early stage required for treatment?
Has amyloid been confirmed in my brain?
What is my personal ARIA risk?
What MRI schedule will I need?
What will Medicare cover, and what will I likely pay?
What are realistic expectations for benefit?

What this means for readers

Anti-amyloid drugs such as lecanemab represent a new treatment option for people with early Alzheimer’s disease in the United States. They may modestly slow cognitive decline, but they do not restore lost memory and they carry real risks that require MRI monitoring.

Eligibility is limited to people with mild cognitive impairment or mild dementia due to Alzheimer’s disease and confirmed amyloid in the brain. Medicare covers FDA-approved drugs under specific conditions, including registry participation.

For families, the decision is personal. It requires weighing potential slowing of decline against safety risks, logistical demands, and costs. A detailed conversation with a neurologist or dementia specialist is essential before moving forward.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.